Intraventricular delivery of HER2 CAR-T cells with the 4-1BB co-stimulatory domain improved mouse survival compared to intracranial delivery (100% vs 50% at Day 100 post-tumor implantation), and furthermore it could eliminate leptomeningeal and multifocal disease (76). Here, ERBB2 is linked to neoplasm.